Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 27.07 percent increase over sales of $15.658 million the same period last year.